United States· US:0990-7715_b0dfadd1-70b5-49f5-8b63-60d3b4e1cbf5
Mannitol
A mannitol product containing mannitol, registered in United States by ICU Medical Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- MANNITOL
- Manufacturer
- ICU Medical Inc.
- Country
- United States (US)
- ATC code
- B05CX04
- ATC class
- Mannitol
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 3, 2026
Packs & prices · 2
- ndc11099077150224 POUCH in 1 CASE (0990-7715-02) / 1 BAG in 1 POUCH / 250 mL in 1 BAG (0990-7715-12)
- ndc11099077150312 POUCH in 1 CASE (0990-7715-03) / 1 BAG in 1 POUCH / 500 mL in 1 BAG (0990-7715-13)
Regulatory notes
Interactions
304 interactions on record for mannitol.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mannitol · interactions on record
304 records
- 14 severe
- 104 moderate
- 5 minor
- 181 info
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- KanamycinA07AA08severe
- NeomycinB05CA09severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mannitol in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaARDEAOSMOSOL MA 20%ARDEAPHARMA, a.s., Ševětín
- PolandMannitol 20% FreseniusFresenius Kabi Polska Sp. z o.o.
- United KingdomBronchitol 40mg inhalation powder capsules with deviceChapper Healthcare
- NorwayAridolPharmaxis
- GermanyAridolPharmaxis Europe Limited
- FranceMANNITOL 10 % AGUETTANT, solution pour perfusionAGUETTANT
- SwitzerlandMannitol 20 % Braun, InfusionslösungB. Braun Medical AG
- SpainBRONCHITOL 40 MG POLVO PARA INHALACION, CAPSULAS DURASPharmaxis Europe Limited
Authorised across Europe · EMA
The same active substance is authorised in 31 EEA countries. Names it is sold under:
- Austria · Mannit Fresenius
- Belgium · Mannitol Viaflo Baxter, Mannitol, Viaflo Baxter
- Bulgaria · Манитол Б. Браун, Манитол Бакстер
- Cyprus · Mannitol Demo, Mannitol Βιοσερ
- Czechia · Ardeaosmosol Ma, Manitol Viaflo Baxter
- Germany · Aridol, Mannit-Lösung Serag
- Denmark · Mannitol Fresenius Kabi, Osmohale
- Estonia · Mannitol Fresenius
- Spain · Manitol Mein, Osmofundina
- Finland · Aridol, Mannitol Braun
- France · Mannitol Aguettant, Mannitol B. Braun
- United Kingdom (Northern Ireland) · Mannitol Baxter Healthcare, Osmohale
- Greece · Mannitol Bradex, Mannitol Cooper
- Croatia · Manitol Hztm
- Hungary · Mannisol A, Mannisol B
- Ireland · Mannitol Baxter Holding, Osmohale
- Iceland · Bronchitol, Mannitol Viaflo Baxter
- Italy · Mannitolo Bioindustria L.I.M, Mannitolo Bioindustria L.I.M.
- Liechtenstein · Bronchitol
- Lithuania · Mannitol Fresenius
- Luxembourg · Mannitol Viaflo, Mannitol Viaflo Baxter
- Latvia · Mannitol Fresenius
- Malta · Mannitol Baxter Holding, Mannitol Monico
- Netherlands · Mannitol Baxter, Osmohale
- Norway · Aridol, Bronchitol
- Poland · Mannitol Baxter, Mannitol Fresenius
- Portugal · Manitol Braun, Manitol Labesfal
- Romania · Manitol Infomed Fluids, Mannitol Vioser
- Sweden · Aridol, Mannitol Fresenius Kabi
- Slovenia · Manitol Hztm
- Slovakia · Infusio Mannitoli, Mannitol Bieffe
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/692f492f-7c63-4afb-8add-2bba44e32a6f GET /v1/drugs/692f492f-7c63-4afb-8add-2bba44e32a6f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "3OWL53L36A",
"rxcui": "6628",
"inchikey": "FBPFZTCFMRRESA-KVTDHHQDSA-N",
"display_name": "MANNITOL",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "INTRAVENOUS",
"spl_meta": {
"8ad3145e-00e7-4412-b9a5-06f00f264f30": {
"match": "brand_token",
"title": "MANNITOL INJECTION, SOLUTION [HOSPIRA, INC.]",
"spl_version": "23",
"published_date": "2026-04-23"
}
},
"productid": "0990-7715_b0dfadd1-70b5-49f5-8b63-60d3b4e1cbf5",
"productndc": "0990-7715",
"dosage_form": "INJECTION, SOLUTION",
"orange_book": {
"appl_no": "019603",
"products": [
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "5GM/100ML",
"product_no": "001",
"approval_date": "Jan 8, 1987"
},
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "10GM/100ML",
"product_no": "002",
"approval_date": "Jan 8, 1987"
},
{
"rs": false,
"rld": false,
"te_code": null,
"strength": "15GM/100ML",
"product_no": "003",
"approval_date": "Jan 8, 1990"
},
{
"rs": false,
"rld": false,
"te_code": "AP",
"strength": "20GM/100ML",
"product_no": "004",
"approval_date": "Jan 8, 1990"
}
],
"appl_type": "N"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "MANNITOL",
"proprietary_name": "Mannitol",
"active_ingred_unit": "g/100mL",
"application_number": "NDA019603",
"marketing_category": "NDA",
"nonproprietary_name": "MANNITOL",
"start_marketing_date": "20190531",
"active_numerator_strength": "20"
}See everything about mannitol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.